Prescriber's Corner
Voxelotor: A Hemoglobin S Polymerization Inhibitor for the Treatment of Sickle Cell Disease
Avani Yenamandra,(1) PharmD, and Dennis Marjoncu,(2) PharmD, BCOP
From (1) Yale New Haven Hospital, New Haven, Connecticut; (2) Methodist University Hospital, Memphis, Tennessee
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Avani Yenamandra, PharmD, 20 York Street, New Haven, CT 06501.
E-mail: avani.yenamandra@ynhh.org
J Adv Pract Oncol 2020;11(8):873–877 |
https://doi.org/10.6004/jadpro.2020.11.8.7 |
© 2020 Harborside™
ABSTRACT
Sickle cell disease (SCD) affects millions of people throughout the world. Hemoglobin S (HbS) polymerization is the fundamental cause of SCD pathophysiology, which leads to hemolysis, increased viscosity, and acute vaso-occlusive episodes. Novel agents have been developed to target the pathophysiology of SCD and decrease the frequency of SCD complications. Voxelotor (Oxbryta) is an HbS polymerization inhibitor that is approved by the U.S. Food & Drug Administration for the treatment of SCD in adults and pediatric patients 12 years and older.
For access to the full length article, please
sign in.
